Clinical Trial Update: Study of Silevertinib With Temozolomide for the Treatment of Newly Diagnosed GBM With Unmethylated MGMT and EGFRvIII [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial evaluating silevertinib in combination with temozolomide for newly diagnosed glioblastoma with unmethylated MGMT and EGFRvIII is curren…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Glioblastoma

Drugs mentioned

• Silevertinib
• Temodar (Temozolomide)

Snippet

Sponsor: Black Diamond Therapeutics, Inc. | Conditions: Glioblastoma (GBM), Newly Diagnosed Glioblastoma | Phase 2 | Status: RECRUITING